ASCO: Pfizer one-ups J&J with Talzenna combo’s broad castration-sensitive prostate cancer win

This post was originally published on here Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer.  | After winning a broader FDA label in metastatic castration-resistant prostate cancer, Pfizer’s combination of Talzenna and Xtandi is claiming a phase 3 win that positions it for a wider castration-sensitive…

How Quickly Will Oil Normalize?

This post was originally published on here Thank you for subscribing to my posts. If you’re not yet a paying subscriber, please consider becoming one. That’ll allow you to DM me with questions and comments. I plan to move my posts behind a paywall in coming months. Subscribing now locks you in at a low…